fbpx

molecules of the month

saridegib

oral SMO inhibitor

Ph. III for Gorlin syndrome

from SAR of in-house library hit

Press release, January 27, 2023

Infinity Pharmaceuticals, Cambridge, MA (Sol-Gel)

oral SMO & Hh pathway inhibitor Ph. III for Gorlin syndrome from SAR of in-house library hit semisynthesis of cyclopamine-derived HH pathway antagonists Press release, January 27, 2023 Infinity Pharmaceuticals, Cambridge, MA (Sol-Gel)
4 mins read

What is it? Saridegib (IPI-926, patidegib) is a Smoothened receptor (SMO) antagonist and hedgehog pathway inhibitor currently in Ph. III trials for Gorlin syndrome. The molecule is a semisynthetic analog of the naturally-occuring SMO antagonist, cyclopamine, and has a long history and originates from Infinity Pharmaceuticals. After a clinical disappointment as an oral therapy for myelofibrosis and chondrosarcoma in 2012, Infinity out-licensed the molecule to PellePharm in 2013, a company later backed by BridgeBio. Recently, it again changed hands from BridgeBio/PellePharm to Sol-Gel Technologies in a ~$75M transaction. Sol-Gel plans to continue development of the molecule for Gorlin syndrome and basal cell carcinomas as a topical treatment to avoid systemic toxicities, giving this older molecule hope of a new life.…


request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.


already a member? log in: